Table 4. Best objective responses (CR and PR) according to dose level and site(s) of disease in 32 patients with evaluable disease.
| Dose level | Overall responder | MIBG responder | CT responder | Bone marrow responder |
|---|---|---|---|---|
| 555 MBq kg−1 (15 mCi kg−1) |
3/6 |
4/6 |
0/1 |
4/5 |
| 666 MBq kg−1 (18 mCi kg−1) |
6/26 |
11/25a |
3/14 |
3/16 |
| Both dose levels | 9/32 (28%) | 15/31 (48%) | 3/15 (20%) | 7/21 (33%) |
Abbreviations: CR=complete response; CT=computed tomography; MIBG=metaiodobenzylguanidine; PR=partial response.
Denominators indicate number of patients evaluable for response at the given site.
a
One patient did not have MIBG scan after the first course of therapy available for central review of response. This patient was not evaluable for response by the MIBG scan, but had disease progression by another modality and is therefore evaluable for overall response.